ACTRN12623000261617已完成1 期
A Phase I, Open-Label Study to Evaluate the Safety and Pharmacokinetics of APC201 in Healthy Volunteers
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
o S/AEs. No significant AEs and none related to IP All skin irritation assessments scored 0. Cmax of plasma diclofenac sodium: Much lower concentration in blood than oral formulation for all participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 85 Years（—）
- 性别
- All
入选标准
- •1. Male or female adult, 18 to 85 years of age, inclusive at the time of screening.
- •2. If female of childbearing potential, subject must be not pregnant as assessed by a pregnancy test at screening and agree to use an acceptable method of contraception (progestogen-only hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide, cap, diaphragm or sponge with spermicide) from enrolment up to 30 days after the study end. Female subject being postmenopausal for at least 1 year or surgically sterile is considered to be of no childbearing potential.
- •3. The subject has a body mass index (BMI) is greater than or equal to 18.5 and less than 40.
- •4. The health status is assessed by the investigator as normal healthy” based on required screening assessments.
- •5. The subject provided written informed consent.
- •6. Subject agrees to maintain the usual activity level throughout the course of the study.
- •7. Subject must agree to not showering, swimming or wetting the treated knee(s) for 2 hours post application.
- •8. Subject must agree to avoid exposing the treated knee(s) to natural or artificial sunlight.
排除标准
- •1. Known or suspected hypersensitivity to NSAIDs (non-steroidal anti-inflammatory drugs), any of the components in either of the investigational products (IPs), or any physical impediment to apply IP on the knees.
- •2. Known presence of gastrointestinal ulcer or any gastrointestinal bleeding within 6 months prior to Day 1.
- •3. Surgery or arthroscopy of knee(s) within one year prior to Day 1.
- •5. Skin disorder that affects palms of the hands or the application site of the knee(s).
- •6. History of diabetes.
- •7. Donation or significant loss of blood (480 mL or more) within 60 days prior to Day 1.
- •8. Administration of an investigational drug within 30 days prior to Day 1.
- •10. Subject treated with systemic or local NSAIDs within 30 days prior to Day 1.
- •11. Smoked or used nicotine-containing products within 6 months prior to Day 1.
- •12. Has used cannabis or any CBD or THC-containing product within 30 days of the screening visit and during the study.
- •13. Subject plans to use any OTC cosmetic tanning lotions to the target knee while on study.
- •14. Abnormal hepatic and renal functions; hematologic changes at screening:
- •The value of Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) is greater than or equal to 2.5 times upper limit of normal;
- •The value of Total bilirubin is greater than or equal to 1.5 times upper limit of normal;
- •The value of Serum creatinine is greater than or equal to 1.5 times upper limit of normal;
- •The value of Hemoglobin is less than or equal to lower limit of normal.
研究者
相似试验
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of MEDI9447 (Oleclumab) in Japanese Patients with Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080224133AstraZeneca12
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080223819AstraZeneca KK9
已完成
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4635 in Japanese Patients With Advanced Solid MalignanciesAdvanced Solid MalignanciesJPRN-jRCT2080224739AstraZeneca KK12
暂停
1 期
A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumour Activity of Adavosertib (AZD1775) in Japanese Patients with Advanced Solid TumoursAdvanced Solid TumoursJPRN-jRCT2080225236AstraZeneca KK12
已完成
1 期
A Phase 1, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti- tumor Activity of AZD9833 in Japanese Women with ER Positive, HER2 Negative Advanced Breast CancerAdvanced Breast CancerJPRN-jRCT2080225373AstraZeneca KK12